MET
Hepatocyte growth factor receptor
As of the edition of 20 October 2026, MET (hepatocyte growth factor receptor, UniProt P08581) has 45 drugs tested at it and 44 companies on the list, 19 on route A and 6 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P08581
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 130
- Disease areas
- Cancer; Lungs and airways; Digestive system; Blood and lymph; Urinary and reproductive; Immune system; Pregnancy and women's health; Skin and connective tissue
- Registered trials of its drugs
- 487
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 6 |
| Active | 7 |
| Went quiet | 13 |
| Stopped | 16 |
| Status not established | 3 |
| Total | 45 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Crizotinib | Marketed | Phase 4 | Ends 2029 |
| Capmatinib | Marketed | Phase 4 | Ends 2032 |
| Savolitinib | Active | Phase 3 | none listed |
| Amivantamab | Marketed | Phase 3 | Ends 2033 |
| Tivantinib | Went quiet | Phase 3 | none listed |
| Tepotinib | Marketed | Phase 3 | Ends 2030 |
| Vebreltinib | Active | Phase 3 | none listed |
| Onartuzumab | Went quiet | Phase 3 | none listed |
| Foretinib | Active | Phase 3 | none listed |
| Gumarontinib | Marketed | Phase 3 | none listed |
| Merestinib | Stopped | Phase 2 | none listed |
| Telisotuzumab vedotin | Marketed | Phase 3 | Ends 2037 |
12 of 45 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 19 |
| Route B | 6 |
| Engaged | 14 |
| Undetermined | 5 |
| Total on the list | 44 |
The other 41 companies at MET
In the product44 companies in all; 41 are not named here, and no score is.
See the 44 companies at MET, ranked, with the facts behind eachRequest access. Nothing is shown until you do.